November 7, 2019
HLS Therapeutics expects Vatespa to transform business
HLS Therapeutics posted $1.9 million net loss in the third quarter 2019, compared to the same period last year, when it was compared to net loss of $19.7 million, boosted by Canadian-based clozaril sales in the last day of Q2.